Abstract: Systems and methods are disclosed for delivering medication to a patient. One such system has an aerosol generator for aerosolizing medication. The generator is located outside the airway of a patient. A chamber is provided for receiving aerosolized medication from the generator. The system has a carrier gas supply tube for delivering carrier gas to the chamber, and an aerosol delivery tube for receiving the aerosolized medication and the carrier gas from the chamber. The aerosol delivery tube delivers the aerosolized medication to the patient. A distal end of the aerosol delivery tube is positioned inside the airway of the patient in order to discharge the aerosolized medication within the patient's airway.

Abstract: Systems and methods are disclosed for delivering medication to a patient. One such system has an aerosol generator for aerosolizing medication. The generator is located outside the airway of a patient. A chamber is provided for receiving aerosolized medication from the generator. The system has a carrier gas supply tube for delivering carrier gas to the chamber, and an aerosol delivery tube for receiving the aerosolized medication and the carrier gas from the chamber. The aerosol delivery tube delivers the aerosolized medication to the patient. A distal end of the aerosol delivery tube is positioned inside the airway of the patient in order to discharge the aerosolized medication within the patient's airway.

Abstract: A self-contained, portable H2/CO2 (air) ratio apparatus has an exhaled breath system, an air analyzing chamber, a hydrogen concentration analyzer, a carbon dioxide (air) concentration analyzer, an air outlet, a computational analyzer and a display unit. The display unit can be a part of the self-contained, portable H2/CO2 (air) ratio apparatus, remotely a part of the self-contained, portable H2/CO2 (air) ratio apparatus, or combinations thereof. The apparatus can assist in the diagnosis of a neonatal patient developing necrotizing enterocolitis and/or lactose intolerance.

Abstract: The present invention is directed to the use of pulmonary surfactants, and particularly pulmonary surfactants containing hydrophobic surfactant-associated proteins B, C or both (i.e., surfactants such as calfactant (Infasurf®), to treat PGD and other adverse effects of lung transplantation.

Abstract: Patients suffering from acute respiratory distress syndrome or acute lung injury are treated by administering to the patients a therapeutically effective dosage of a surfactant that includes SP-B and phospholipid at a concentration of SP-B relative to concentration of phospholipid that is sufficient to produce detectable SP-B dependent activity.

Abstract: The present invention describes compositions of biologically active surfactant proteins SP-B and SP-C of high purity and high-yield methods for isolating SP-B and SP-C.

Abstract: The present invention relates to the method of using a composition of matter that maintains the biophysical and physiological characteristics of natural surfactant, including the rapid and spontaneous adsorption of dilute suspensions to an air-liquid interface; the generation of low surface tension (<2.1 mN/m) at a surface area compression of 50% by the pulsating bubble method of Enhorning; and the restoration of greater than 75% of the lost volume of a surfactant deficient lung as determined by the method of Bermel. The material is produced by adding disaturated phospholipid to the extract of surface active material obtained by lavage of the air space of the lungs of animals. The material contains 90-96% phospholipid, 0-6% cholesterol, and 1-3% protein. Greater than 99% of the protein is lung surfactant apoproteins B & C. A sterile pharmaceutical preparation of the surface active material can be used for treating diseases caused by deficiency or dysfunction or natural lung surfactant.

Abstract: The present invention describes compositions of biologically active surfactant proteins SP-B and SP-C of high purity and high-yield methods for isolating SP-B and SP-C.